IBIS-II Bone Mineral Density Changes
New online tool for clinicians could predict risk of breast cancer returning
Screening for breast cancer genes 'is cost-effective'
Jack Cuzick Wins Academic Innovation Award
Cancer researcher wins Lifetime Achievement Award
14 Feb 2017 | Half of GPs unaware of Tamoxifen for Cancer Prevention
30 Dec 2016 | IBIS-II Chair Jack Cuzick appointed CBE in honours from the Queen
03 Dec 2016 | NICE recommends Anastrozole for breast cancer prevention in high risk women
06 June 2016 | Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life
06 June 2016 | First major trial to see if losing weight reduces the risk of cancers coming back is about to start in the US and Canada
29 April 2016 | Dr Cuzick, IBIS Co-Chairman elected as a new Fellow of the Royal Society
12 Dec 2014 | Medical News Today | Tamoxifen has reduced breast cancer rates 'by a third'
11 Dec 2014 | YouTube | Dr. Cuzick on decreasing breast cancer risk with tamoxifen
12 Dec 2014 | The Telegraph | Call for wider use of breast cancer drug
11 Dec 2014 | Cancer Research UK | Tamoxifen protects against breast cancer in long-term
11 Dec 2014 | The Pharmaceutical Journal | Chemoprevention with tamoxifen cuts risk of breast cancer by almost 30%
11 Dec 2014 | Los Angeles Times | Breast cancer prevention drug gives lasting protection, study finds
11 Dec 2014 | The Telegraph | Tamoxifen could protect women from cancer for 20 years if taken daily
11 Dec 2014 | The Guardian | Breast cancer drug tamoxifen has long term effect, study finds
13 Dec 2013 | MSNBC | Breast cancer drug to save lives of thousands of women
12 Dec 2013 | King 5 | Study: Hormone-blocker slashes breast cancer risk
12 Dec 2013 | CBS News | Anastrozole reduces breast cancer drug chance by 53 percent, study says
12 Dec 2013 | The Telegraph | 'Remarkable' breast cancer drug could save lives of thousands of women
12 Dec 2013 | ABC News | Drug Halves Breast Cancer Occurrence in Women at High Risk
12 Dec 2013 | Sky News | Breast Cancer Drug 'Halves' Risk In Many